UCSF Researcher Identifies Risk Genes for ALS

Broad Data Analysis Points to Genetic Similarities between Lou Gehrig’s Disease and a Form of Dementia

stock illustration of neurons

The largest analysis to date of genetic data in amyotrophic lateral sclerosis (ALS) – the muscle-crippling neurodegenerative disease that afflicted the late astrophysicist Stephen Hawking and cut short the career of iconic Yankee baseball slugger Lou Gehrig – has identified two previously unrecognized genetic risks that are significantly associated with the disease.

In the new study, published April 9 in JAMA Neurology, scientists from UC San Francisco and Washington University found that one of the newly identified ALS-associated genetic variants also is a risk factor for another neurodegenerative disease, frontotemporal dementia (FTD), which typically weakens a different set of brain functions.

Many questions remain about the distinctions and similarities between the start and progression of ALS, which affects about 30,000 people in the United States, and that of other neurodegenerative diseases, such as Alzheimer’s, Parkinson’s and FTD.

Headshot image of Rahul Desikan, MD, PhD
Rahul Desikan, MD, PhD, study's co-author

Alzheimer’s disease, in particular, has been associated with other neurodegenerative disorders and even shares risk factors with cardiovascular disease, according to Rahul Desikan, MD, PhD, an assistant professor with the UCSF Department of Radiology and Biomedical Imaging and corresponding author for the new study. But to some extent, ALS seems to stand apart from these other disorders in terms of the genetic mutations that appear to elevate disease risk, he said.

"In this study we found that ALS is closely related genetically to frontotemporal dementia, but not to any of the other common neurodegenerative diseases, like Alzheimer's or Parkinson's,” Desikan said.

The study, a broad analysis of data from previous studies, was led by Desikan and by co-corresponding author, Celeste Karch, PhD, an assistant professor with the Department of Psychiatry at Washington University, in St. Louis.

Scientists hope that identifying genetic mutations in neurodegenerative diseases, along with the biochemical processes affected by these gene mutations, will shed greater light on how these diseases arise and how they might be treated.

Shared Symptoms Between ALS and FTD

ALS typically is fatal, as the degeneration of neurons in the frontal region of the brain that controls muscles causes sufferers to lose motor control, as well as the ability to speak and, ultimately, the ability to breathe. As with other neurodegenerative diseases, abnormal accumulation of specific proteins within neurons appears to play a role. However, causes and fundamental biological mechanisms of disease progression have not been clearly defined. There is no cure, although in recent years treatments have been approved that appear to slow disease progression.

While ALS most strikingly affects nerve cells in the brain that enable muscle movement, FTD primarily targets a different set of neurons and is characterized predominantly by progressive behavioral inappropriateness and loss of inhibition, as well as by cognitive decline. However, it has become clear that individuals with FTD may also experience symptoms often associated with early stages of ALS, such as weakness, loss of coordination, muscle spasms, rigidity, tremor and difficulty swallowing. Conversely, in close to half of cases, those afflicted with ALS experience cognitive symptoms. The two diseases now are regarded to be part of the same disease spectrum.

Meta-Analysis of Previous Studies

For their new analysis, the researchers pooled data from previous genome-wide association studies that included genetic data from 124,876 individuals of European ancestry. The studies included healthy controls, as well as individuals affected by ALS; Alzheimer’s; Parkinson’s; FTD; corticobasal degeneration (CBD), which kills neurons in the cerebral cortex and other brain regions; and progressive supranuclear palsy (PSP), a disease that affects gait and movement, including eye movement, but which is clinically distinct from Parkinson’s.

Desikan and Karch were especially interested in identifying genetic variations that would appear in identical form in different individuals, but that might result in elevated risk for different diseases, pointing to varying effects on the molecular or cellular level. In their meta-analysis of previous study, they applied statistical methods that have been developed to identify individual bits of DNA in which mutations or inherited variations may be associated with more than one disease.

The researchers found that a specific variation in a region of DNA containing the gene for microtubule-associated protein tau (MAPT), also known as tau protein, was associated with elevated risk for ALS. Specific mutations in tau previously have been associated with other neurodegenerative diseases, and abnormal tau accumulation has been observed in brain regions affected by Alzheimer’s. Different mutations in the tau gene often have been associated with different neurodegenerative diseases. The specific genetic variant identified in the new study was associated only with ALS, not with the other diseases included in the study.

The other major, new finding of the study was a genetic variation that is associated with both ALS and FTD, and which affects production in the human brain of a protein called BNIP1. BNIP1 is required for the normal function and development of neurons. Levels of BNIP1 have been found to be diminished in motor neurons isolated from the spinal cords of ALS patients after death, and in a mouse model for ALS. Lower levels also have been measured in the brains of patients with FTD or PSP.

Bruce Miller, study co-author
Bruce Miller, study's co-author

“Desikan has shown the remarkable capacity to explore huge data sets, using novel data mining and statistical approaches that are uncovering our individual risks for different neurodegenerative disorders,” said study co-author and FTD expert Bruce Miller, the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at UCSF, and director of the UCSF Memory and Aging Clinic, at UCSF Weill Institute for Neurosciences.

Learning More from Big-Data Approach

A large majority of ALS cases arise sporadically. Genetic variations that modestly elevate risk for ALS have been identified in association with more than two dozen different genes. Non-genetic risks, such as environmental exposures, are also believed to play a role. In addition, roughly 10 percent of ALS runs in families, and among these families several common causative gene mutations have been identified that account for most familial cases.

ALS is not uniform in time course or symptomology. The disease usually progresses steadily from the time of diagnosis. According to the ALS Association the average age of onset is 55. Only about 10 percent of those newly diagnosed with ALS survive 10 years or more. Hawking, who died on March 14, was a notable exception, as he was diagnosed as a young adult and lived to be 76.

According to Desikan, additional large genetic studies may illuminate how subtly different neurodegenerative processes arise in association with different mutations, including genetic variations that differ only slightly from one another.

“I think this kind of big-data approach can point us in the right direction on where to start for better understanding ALS, which remains poorly understood," he said.

Additional study authors include Natalie Wen from Washington University; Chun C. Fan, MD, and Anders M. Dale, PhD, from UC San Diego; Jennifer S. Yokoyama, PhD, and Christopher P. Hess, MD, PhD, from UCSF; Naomi Kouri, PhD, and Owen A. Ross, PhD, from Mayo Clinic College of Medicine; Gunter Höglinger, MD, from the Technical University of Munich; Ulrich Müller, MD, from Justus-Liebig-Universität; Raffaele Ferrari, PhD, and John Hardy, PhD, from University College London; Gerard D. Schellenberg, PhD, Vivianna Van Deerlin, MD, PhD, and Patrick M. Sleiman, from the University of Pennsylvania; Parastoo Momeni, PhD, from Rona Holdings; Manu Sharma, PhD, from the University of Tübingen; and Olav B. Smeland, MD, PhD, and Ole A. Andreassen, MD, PhD, from the University of Oslo.

The researchers were awarded major funding for the study from the National Institutes of Health, and from the American Society of Neuroradiology.

UC San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, transitional and population sciences; and a preeminent biomedical research enterprise. It also includes UCSF Health, which comprises three top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children's Hospitals in San Francisco and Oakland, and other partner and affiliated hospitals and healthcare providers throughout the Bay Area.